brain), probably because of its contribution to cellular diversity, which provides a selective advantage in response to injuries. Binucleated and polyploid hepatocytes are detectable in mice few weeks after birth.
1 They can revert to diploidy and become aneuploid, 2 while diploid liver cells can increase their ploidy.
This dynamic mechanism, defined as "ploidy-conveyor," 3 generates aneuploidy and has also been reported in human hepatocytes. 4 Under conditions of stress, hepatocytes acquire specific aneuploidies enabling them to resist to chronic liver injuries. 5 Moreover, aneuploid neurons, retaining functional activity, 6 have been observed in developing and adult murine models 7, 8 and in the human brain. 9, 10 The majority of studies have reported a prevalence of aneuploid cells exceeding 50% and 20% in the liver 3,4 and brain, 7, [10] [11] [12] respectively. However, SKY and FISH approaches, which have been used for karyotype analysis, may overestimate aneuploidy. Indeed, a recent single cell sequencing study revealed that even in liver and brain tissues, aneuploidy accounted for less than 5% of all cells 13 under physiological conditions. In different tissues, aneuploidy is associated with aging and age-related disorders.
Mice expressing reduced levels of the spindle assembly checkpoint (SAC) component BUBR1, which is mutated in the majority of patients with Mosaic Variegated Aneuploidy (MVA) syndrome, develop progressive aneuploidy and agerelated defects including cataracts, loss of subcutaneous fat, skeletal muscle wasting, lordokyphosis, impaired wound healing [14] [15] [16] and cerebral degeneration, 17 with deficits in neural progenitor proliferation and maturation. 18 In oocytes, the frequency of chromosome segregation errors in meiosis I increase with maternal aging, 19 along with a decrease in BUBR1 protein. 20 The aneuploid condition may also favor neurodegeneration during aging. The APP gene, which encodes for the protein forming amyloid β plaques in Alzheimer's disease, is located on chromosome 21. Individuals with Down's syndrome frequently develop this neurodegenerative disorder by the age of 40, 21 and buccal cells from patients with Alzheimer's disease frequently carry trisomy of chromosomes 21 or 17, where many susceptibility genes are located. 22 These findings suggest that a low frequency of aneuploid cells can be tolerated 13 or may even be advantageous under specific conditions in nonmalignant tissues, 23 whereas increased rates of aneuploidy can become pathogenic, as observed in neurodegenerative diseases 22 and in cancer. 24 Theodor Boveri initially suggested that an abnormal chromosome number causes tumorigenesis. 24 Over the past 100 years, a number of studies have investigated the cellular and molecular events that cause aneuploidy and studied its potential involvement in cancer development. Here, we describe SAC gene alterations across tumors and their link with neoplastic transformation. We also focus on the complex relationship between aneuploidy and cancer, including the oncogenic and tumor suppressor functions of the abnormal chromosome number and its therapeutic potential.
The Spindle Assembly Checkpoint in Aneuploidy Generation and Cancer
Aneuploidy in mitotically dividing cells can result from numerous defects, including mitotic slippage, cytokinesis failure, spindle multipolarity, defective kinetochore-microtubule attachments, perturbed microtubule dynamics, cohesion defects, and impaired SAC function. 25, 26 The SAC prevents entry into anaphase and premature chromosome segregation until all kinetochores are properly attached to the mitotic spindle. This function is achieved through assembly of the mitotic checkpoint complex (MCC), the SAC effector, which inhibits the activity of the anaphase-promoting complex/ cyclosome (APC/C) CDC20 . 27 Briefly, when the SAC is satisfied, the MCC is disassembled and APC/C CDC20 drives ubiquitination and proteolytic degradation of cyclin B1 and securin. These events induce mitotic exit and sister chromatid separation by degradation of the cohesin complex.
A weakened SAC may allow cells to enter anaphase in the presence of unattached or misaligned chromosomes and both copies of one chromosome may be deposited into a single daughter cell (Fig. 1) . Thus, failure of the SAC machinery is an obvious candidate mechanism involved in the generation of aneuploidy during mitosis. However, the genes encoding SAC proteins (including MAD1L1, BUB1, BUB1B, CDC20, BUB3, and MAD2L1) are rarely mutated in human cancers. A mutation frequency exceeding 5% has been only detected in uterine corpus endometrial carcinoma (9.6, 7.4, 6.2, 6.4, and 7.6% of patients carrying MAD1L1, BUB1, BUB1B, CDC20, or BUB3 mutations, respectively) and colon adenocarcinoma (5.5% of patients with MAD1L1 or BUB1 mutations) according to next generation sequencing data from The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/, Fig. 2 ). On the contrary, SAC genes are deregulated at mRNA and protein level in a number of tumors (Table 1) , suggesting potential alterations of epigenetic, transcriptional and posttranscriptional regulation. For example, mutations of oncogenic or tumor suppressor pathways can lead to deregulated SAC gene expression. There is evidence that inactivating RB mutations cause deregulation of the E2F family of transcription factors resulting in MAD2 overexpression 28 and chromosome instability (CIN), which have also been detected in a p53 mutant mouse model. 29 With the exception of a few reported cases of reduced expression, SAC genes are generally overexpressed in primary tumors (Table 1) . High expression levels associate with elevated proliferation index and metastatic potential and predict advanced stage, reduced overall survival, disease-free survival and recurrence-free survival across several cancer types, including solid tumors, and hematological malignancies. This observation appears in contrast to the fact that aneuploidy occurs in cases of defective SAC. However, both increased and decreased SAC gene expression induces aneuploidy and favors tumor development, as demonstrated in mice ( Table 2 ). The protumorigenic or antitumorigenic effect is also dependent on the specific SAC gene which is overexpressed or downregulated. For example, CDC20 overexpression impairs SAC function and favors aneuploidization in oral cancer. 30 Moreover, chromosome missegregation and aneuploidy have been reported in both transgenic (tg), hypomorphic and haploinsufficient mouse models, including MAD2-tg 31 and mad2
bub1 −/H and bub1 H/H . 35 These findings suggest that expression of some SAC genes above threshold levels is required to maintain genomic stability and prevent tumorigenesis, as shown in the bub1 +/− model, characterized by higher levels of BUB1 protein compared to bub1
H/H and bub1 −/H mice and lower tumor incidence. 35 However, SAC gene deficiency is also detrimental, probably due to extreme CIN. 26 Indeed homozygous deletion of many SAC components causes early embryonic lethality. Conversely, the protumorigenic effect of SAC gene overexpression may be linked to delayed mitotic exit, which induces aneuploidy (e.g., MAD2 overexpression stabilizes securin and cyclin B and inhibits cytokinesis 28, 31 ), and to potential oncogenic roles of SAC proteins outside mitosis: BUBR1 plays a role in DNA damage responses, 36 CDC20 is involved in the regulation of apoptosis, 37 DNA repair 38 and stem-like cell properties [39] [40] [41] and MAD1 has a function at the Golgi apparatus. 42 This complex scenario suggests that both increased and decreased SAC gene expression may favor tumorigenesis, depending on the threshold level, the gene functions inside and outside mitosis, the effect on chromosome stability, the cell type and its genomic background.
Tumor-Protecting and Tumor-Promoting Effects of Aneuploidy
The complex and much debated relationship between aneuploidy and cancer fosters a very active research field. There is evidence to suggest that aneuploidy can exert an antitumorigenic or a protumorigenic effect (Fig. 3) . Studies on yeast strains, murine and human cells have shown that aneuploidy impairs the proliferative capacity of nonmalignant cells and that the phenotype is independent of the identity of the individual chromosomes, while being potentially proportional to its size. [43] [44] [45] [46] [47] [48] Changes in chromosome copy number result in transcriptomic alterations and gene-dosage effects at the proteomic level, as extensively reviewed by Ried et al. 49 These in turn lead to an imbalance in the cellular protein composition, which may saturate the protein folding and degradation machineries, thus eliciting a proteotoxic stress response and altering the redox anabolic homeostasis, leading to increased reactive oxygen species (ROS). 50, 51 These findings indicate that aneuploidy is generally disadvantageous for cells and there is ample evidence of the negative effect of aneuploidy on the fitness of nonmalignant cells (Fig. 3a) . First, aneuploidy is an extremely rare event in normal conditions, even in brain and liver. 13 Second, trisomic murine embryonic fibroblasts (MEFs) show contact inhibition properties, proliferation arrest in low- serum medium, lack of clonogenic capacity and senescence features after 7-10 passages in culture. 52 Third, trisomic cells can revert to the euploid state by losing extra chromosomes both in vitro and in vivo in order to improve their growth capacity. 52 Accordingly, human fibroblasts from patients with constitutional triploidy show moderate levels of somatic mosaicism due to the progressive accumulation of cells that undergo whole chromosome loss. 53 Moreover, constitutional aneuploidy per se is not sufficient to generate tumor-like CIN. 53 Aneuploid cells modulate their metabolic and transcriptional programs to improve their fitness. Indeed, aneuploidy is associated with higher glucose and/or glutamine consumption 46, 48 and with changes in the expression of proteins involved in cell cycle, ribosome biogenesis, endoplasmic reticulum, Golgi apparatus, lysosomes, membrane metabolism, the major histocompatibility complex (MHC) protein complex and antigen processing, DNA replication, transcription, energy production, and response to stress. 44, 45, 54 These pathways are deregulated in several aneuploid cell lines, although the specific combinations of genes displaying altered expression differ. 51 These observations, mostly obtained from trisomic models, indicate that single-chromosome aneuploidy is not sufficient per se to induce malignant transformation 52 but rather has antitumorigenic properties. Accordingly, individuals with Down's syndrome display a reduced incidence of solid tumors, including breast, lung, and prostate cancers, suggesting that trisomy 21 is a protective event against malignant transformation in those tissues. 55 Moreover, some mouse models with deregulated SAC genes that develop aneuploidy have a decreased rate of tumorigenesis (Table 2) , even under 157, 186 (Continues)
Simonetti et al. various oncogenic backgrounds. Recently, Benezra's group showed that individual chromosome loss in tetraploid MEFs may drive tumorigenesis by favoring anchorage-independent growth, DNA damage, and CIN. 56 These results are highly relevant within the context of tumors with increased ploidy and may suggest a difference between the tumorigenic potential of chromosome gain and loss. However, single-chromosome loss did not induce transformation of diploid MEFs, indicating a ploidy-specific effect. Moreover, single-chromosome loss hampered the proliferative capacity of diploid hematopoietic cells, in line with previous studies reporting a negative effect of single-chromosome gain under normal ploidy.
Despite the detrimental effect of chromosome number alterations on cellular fitness, aneuploidy is one of the hallmarks of cancer, a disease of cells undergoing uncontrolled proliferation. According to the Mitelman Database, about 90% of solid tumors and 50% of hematological neoplasms are aneuploid. 57 How can this be reconciled with the findings described so far in this section?
Although in vitro culturing of fibroblasts from patients with constitutional aneuploidy have shown that whole chromosome gains do not confer levels of CIN comparable to those observed in cancer cells, 53 several studies indicate a correlation or a causal relationship between aneuploidy and genome/CIN. A correlation between the two phenomena has been observed in monosomic and trisomic models. Amniocytes from trisomic fetuses display a higher incidence of random aneuploidy, 58 and lymphocytes from patients with Turner's syndrome or constitutional autosomal trisomy (of chromosome 21, 18, or 13) are prone to develop nonchromosome specific aneuploidy under phytohemagglutinin stimulation. 59, 60 Moreover, genomic instability (GIN) is proportional to the degree of aneuploidy in transformed Chinese hamster embryo cells. 61 GIN and CIN are key features of the adaptive response driven by aneuploidy and favoring malignant transformation (Fig. 3b) . Singlechromosome aneuploidy is sufficient to induce CIN, an increase in double strand break (DSB) during DNA replication and defective DSB repair, resulting in a "mutator phenotype" in yeasts. 62 Indeed, yeast strains with high proliferative capacity display aneuploidy-tolerating mutations, 63 including both strain-specific genetic lesions and common mutations shared between different aneuploid strains. Common lesions mainly target the ubiquitin-proteasome machinery, with recurrent lossof-function mutations in the gene encoding the deubiquitinating enzyme UBP6. Therefore, aneuploidy is maintained and propagated through the positive selection of cells that evolve and become fitter. Increased DNA damage, genomic rearrangements and replication stress have also been reported in human cells as a consequence of aneuploidy. 64 In particular, chromosome segregation errors (specifically chromatin bridges, which typically arise as a result of DNA damage) can lead to the accumulation of postmitotic DNA damage due to the "trapping" of chromatin bridges in the cleavage furrow. 65 Moreover, trisomic colon cancer cells display a higher rate of chromosome missegregation than that of euploid ones, 66 and the capacity of accurate chromosome segregation decreases in a discontinuous way compared to chromosome number changes. 67 Indeed, yeast cells with a ploidy between 1.5 and 2 are more susceptible to chromosome missegregation than those with a near haploid karyotype. 67 This evidence suggests that additional numerical and structural chromosomal aberrations exacerbate genomic complexity in aneuploid cells. It was recently suggested that replicative stress caused by aneuploidy 64 and oncogenic alterations targeting TP53, RB, 29 or KRAS 68 induce CIN, 69 even in the absence of mutations in genes involved in chromosome segregation or mitotic checkpoint. For example, in immortalized colonic epithelial cells that acquire an extra copy of chromosome 7 under the selective pressure of serum-free culture conditions, the expression of oncogenic KRAS or the depletion of TP53 predispose to the acquisition of trisomy 20. 70 Thus, the progressive accumulation of mutations, translocations and/or copy number variants improves cell tolerability toward the negative consequences of the altered chromosome number and promotes cell growth, as demonstrated in yeasts, trisomic MEFs 52 and human cell lines. 64 Moreover, aneuploidy confers an evolutionary flexibility that may contribute, along with oncogenic events, to the cellular heterogeneity observed in cancer and to the aggressive phenotype of advanced malignancies with complex karyotypes.
Aneuploidy itself is an evolutionary strategy to compensate for the deletion of evolvable genes in yeasts. Although, these genes regulate essential cellular processes (e.g., Golgi vescicle trafficking, nuclear transport and nuclear pore complex, protein targeting to endoplasmic reticulum), the cells can survive their loss by developing alternative strategies, including altered gene dosage induced by aneuploidy. 71 For example, aneuploidization can correct failure of cytokinesis in MYO1-deficient yeasts. 72 Altered levels of transcription factors encoded by aneuploid chromosomes induce changes in the expression of downstream genes involved in cytokinesis. Different patterns of aneuploidy, arising in the absence of MYO1, converge to common targets capable of restoring cytokinesis.
Specific biological and metabolic properties contribute to the adaptive response induced by aneuploidy (Fig. 3b) . Aneuploid cells show heightened anchorage-independent growth and migration capacity (e.g., in a colorectal model 23 ). In human pluripotent stem cells (hPSCs), aneuploidy inhibits differentiation propensity and apoptosis, increases proliferation and favors the formation of teratomas characterized by a gene expression profile resembling that of germ cell tumors. 43 Aneuploid cells can also redistribute their resources to overcome functional defects. 73 For example, yeast cells use aneuploidy to survive telomerase insufficiency by increasing the expression of the telomerase components at the expense of ribosome synthesis. 73 The deregulated expression of genes that are involved in oxidative phosphorylation and that protect from oxidative stress also contributes to the tumor-promoting effect of aneuploidy. Yeasts can adapt to deficiency of all thiol peroxidases, the enzymes that alleviate oxidative stressmediated DNA damage, by acquiring an extra copy of chromosome XI. 74 This allows the removal of hydrogen peroxide through increased expression of the mitochondrial proteins CCP1 and UTH1 and enforced respiration. Therefore, the evolutionary flexibility induced by aneuploidy is not only an attempt to survive a disadvantageous chromosome number, but also a favorable condition in some settings. A recent study suggested a role of aneuploidy in immune escape 75 (Fig. 3b) . Most aneuploid tumors show decreased neoantigen load, possibly mediated by limited neoantigen generation and presentation through the MHC complex. This, in turn, results in decreased immune cell infiltration and makes aneuploid neoplasms less responsive to immunomodulating agents.
Overall, evidence obtained in nonmalignant cells and cancer models indicates that aneuploidy, which is detrimental per se, can be beneficial and even favor the development and selection of aggressive malignant clones by enabling cells to modulate independent pathways simultaneously and to explore a wide phenotypic landscape.
Aneuploidy and Cancer: Cell Type, Genomic Background and Environmental Conditions Matter
Although Down's syndrome patients have a 10-fold lower solid tumor-related mortality than the general population, they are more likely to develop leukemia. 55 A gain of chromosome 21 is a common event in sporadic leukemia, is the most frequent karyotypic alteration in acute lymphoblastic leukemia, but is rare in glioblastoma, breast, and colorectal cancer. 76 These observations are suggestive of a tissue-and chromosomespecific oncogenic effect of aneuploidy. Accordingly, malignant transformation does not occur randomly in the majority of transgenic and knock-out mouse models of aneuploidy (Table 2 ). MAD2 overexpression specifically increases the susceptibility to hepatoma and hepatocellular carcinoma, lung adenoma, fibrosarcoma, and lymphoma. 31 Reduced BUB1 expression favors the development of thymic lymphoma and colon cancer in tp53 +/─ and apc Min/+ mice, respectively, but suppresses prostatic intraepithelial neoplasia in pten +/─ mice and does not alter the frequency of pituitary tumors and sarcoma formation in the rb +/─ model. 77 Moreover, cultured hPSCs tend to acquire trisomy of chromosome 12, which is the most common chromosomal aberration in germ cell tumors, 43 and trisomy of chromosome 13, which confers a distinctive cytokinesis failure phenotype to colon cancer cells. 66 Although the spectrum and degree of aneuploidy differ among tumors, many human cancers share recurrent aneuploidies. 78 It is currently believed that tumor-specific aneuploidies coexist with recurrent aneuploidies across tumors. Using a computational approach, Davoli et al. showed that chromosome number alterations do not occur randomly: a selective pressure forces the acquisition of oncogenes and the loss of tumor suppressors, 79 as observed in yeast cells that overcome MYO1 deficiency by preferential gain of specific chromosomes. 72 Aneuploidy also improves cellular adaptation to specific biological and environmental features. In nonpathological conditions aneuploidy is well tolerated under "population flush" effects, 80 when rapid cell expansion is needed (e.g., during embryogenesis) and in nonregenerating tissues, as brain and liver, in which the nonproliferative cellular status is protective against the potentially dangerous consequences of aneuploidy. On the contrary, aneuploidy is physiologically selected against in tissues that undergo self-renewal, including the hematopoietic compartment, skin, and intestines. 81 However, aneuploidy improves the survival rate under conditions of stress, including extreme temperature or pH, lack of nutrients, and incubation with chemotherapeutic or antifungal agents in budding yeasts. 44 Similarly, trisomic colorectal cancer cell lines have a proliferative advantage over euploid cells under hypoxic conditions, chemotherapeutic pressure and in conditions of serum starvation. 23 Serum-free conditions also favor the acquisition of trisomy 7 in immortalized human colonic epithelial cells. 70 The pathogen Candida Albicans develops aneuploidy, mainly consisting in chromosome 5 trisomy (or gain of an isochromosome composed of the two left arms of chromosome 5), as an adaptive strategy to resist fluconazole, commonly used to treat fungal infections. 82 The aneuploid strain has an increased growth rate compared to the wild-type strain under fluconazole pressure, but this advantage is lost in the absence of the drug. Moreover, the accumulation of multiple trisomies of chromosome 3-7 during fluconazole treatment increases resistance, while also having a low fitness cost under nonselective conditions in this model. 83 Similarly, Chen et al. showed that dynamic karyotype changes allow yeast cells to survive drug exposure. 84 This complex scenario recapitulates tumor biology given that both cancer and leukemia stem cells localize mainly in hypoxic niches. If we consider aneuploid cells as a premalignant state, their genomic plasticity confers the ability to evolve to a malignant phenotype in order to tolerate adverse environmental conditions. The DNA replication stress, which fuels defective chromosome condensation and segregation in aneuploid hPSCs, 69 may also propagate GIN in cancer stem cells. Karyotypic heterogeneity may in turn result in phenotypic variations, thus allowing specific aneuploid cells to be fitter under conditions of stress, including oncogene withdrawal and pharmacological treatment. CIN induced by MAD2 overexpression sustains tumor progression and recurrence upon oncogene inactivation in Kras G12D models of breast 85 and lung 68 cancer, respectively, through activation of alternative oncogenic signaling pathways. In human and murine medulloblastoma, GIN and aneuploidy are common features of the malignant clone driving relapse, which originates from a minor clone present at diagnosis and selected by therapy. 86 Similarly, CIN and aneuploidy characterize chemotherapy-resistant subclones, giving rise to metastases in breast cancer. 87 This suggests that aneuploidy, when causing moderate levels of genetic instability, can improve adaptation to the microenvironmental conditions in a specific tumor site, without compromising cell viability.
Therapeutic Potential of Aneuploidy in Cancer Patients
Recent studies have shown that exacerbating chromosome missegregation rates in aneuploid cells by combining heterozygous deletions of the centromere-linked motor protein cenp-E and of the SAC component mad2, results in high CIN levels and leads to tumor suppression in mice due to the induction of cell death. 88 High CIN levels sustain tumorinitiating cells while depleting mature tumor cells. 89 For example, CENP-E reduction in apc Min/+ mice does not inhibit the formation of intestinal tumors but hampers their progression. 89 This suggests a dual relationship between aneuploid malignancies and antitumor therapeutic strategies: aneuploidy can be a cancer strength or an Achilles' heel.
According to two different clinical trials on metastatic melanoma, aneuploidy promotes cancer immune escape and correlates with bad prognosis in response to immune checkpoint blockade agents. 75 However, chromosomally unstable tumors, such as those with aneuploidy, may be induced to mitotic catastrophe by drugs interfering with chromosome segregation, in particular by enhancing the chromosome missegregation rate. 90, 91 These include compounds that disrupt microtubule dynamics either by inducing overpolymerization (stabilizing drugs, e.g., taxanes) or by reducing polymerization (destabilizing drugs, e.g., vinblastine), or drugs that disrupt the kinetochore-microtubule attachment, correction of misattachments (e.g., Aurora B inhibitors) or SAC activity. For example, the microtubule-stabilizing drug paclitaxel kills breast cancer cells by inducing chromosome missegregation on multipolar spindles. 92 These preclinical tests need to be substantiated by clinical studies. Recently, a clinical trial to compare paclitaxel response with CIN level in breast cancer patients began its recruitment phase (NCT03096418, https://clinicaltrials.gov). The downside of mitotic drugs is their severe bone marrow toxicity. However, this can be prevented by ad hoc combination therapies, including a chemotherapy backbone, aimed at tumor debulking, disease eradication, and a reduction in side effects. The controversial role of the mitotic checkpoint in the response to antimitotic drugs 93 should also be taken into account when designing clinical trials. A successful approach can be built on the concept of synthetic lethality, which refers to the simultaneous perturbation of two genes resulting in the death of the cell or the organism. Certain drugs can cause lethality in malignant cells carrying structural or functional alterations in specific genes or pathways. For example, cancer cell lines with defective chromatid cohesion are resistant to paclitaxel but highly responsive to SAC inhibition, 94 and knock-down of Ppp2r1a is lethal in MAD2 overexpressing tumors. 95 These "lethal" combinations should be exploited to target aneuploidy-supporting cellular functions. Indeed, in addition to their neutropenic effects, mitotic drugs are not expected to be effective against tumors showing a negative correlation between CIN and survival. The strength of these aneuploid tumors resides in their increased tolerability toward stress conditions, their genomic complexity and stem cell-like quiescence, which probably favor resistance to chemotherapy and maintenance of proliferative capacity, 96 driving progression to a very aggressive phenotype.
The aneuploid cell-dependence on chaperone pathways and heightened protein turnover suggest additional therapeutic potential, exploiting proteotoxic stress as aneuploidy-related vulnerability. Aneuploid MEFs, hPSCs, human embryonic stem cells, colorectal cancer cell lines and induced (i)PSCs from trisomy 21 fibroblasts are sensitive to compounds, inhibiting protein folding (17-(Allylamino)-17-demethoxygeldanamycin), or inducing energy stress (aminoimidazole carboxamide ribonucleotide) although a comparison between aneuploid and euploid cells, led to different results among the models. 43, [97] [98] [99] Moreover, hPSCs with trisomy 12 showed enhanced sensitivity to drugs targeting DNA replication, including etoposide, cytarabine and gemcitabine hydrochloride, compared to euploid cells. 43 Taken together, these findings indicate that the aneuploid condition offers a therapeutic window for specific antitumor treatment strategies.
Conclusions
An improved understanding of the molecular mechanisms of aneuploidy and of its consequences on cell physiology has provided important insights into the complex relationship between chromosome number alterations and cancer. Aneuploidy can increase malignant cell strength while also creating vulnerability to specific conditions or therapeutic interventions. The tissue type, genetic background and microenvironment play a pivotal role in the match. However, the genetic determinants of the protumorigenic or antitumorigenic effects of aneuploidy and their interplay with the biology of the cell of origin remain unclear. Altered expression of SAC components is a common feature across cancer types and minority of cases carry mutated SAC genes, which may interfere with chromosome segregation fidelity. However, chromosome segregation represents a rapid event in the eukaryotic cell cycle. Cells exiting the quiescent G0 phase accumulate mass, activate signaling pathways, replicate the genome and prepare for mitotic division through G1, S and G2 phases. Dysfunction of cellular components involved in these stages through either mutations, copy number alterations, epigenetic modifications, or deregulated expression may compromise mitotic fidelity and favor aneuploidy. Thus, the identification of genomic patterns that associate and/or synergize with aneuploid phenotypic profiles in promoting tumor development might be a prerequisite to any therapeutic decision, along with the definition of chromosome missegregation frequencies inducing adaptive levels of CIN. These approaches will unravel the relationship between genetic variability, drug resistance and acquisition of stem cell characteristics, while also defining lineage-specific vulnerabilities for aneuploid tumors. Such knowledge, complemented by the availability of rationally designed targeted agents that have produced promising results, will serve as a map for personalized synthetic lethal therapeutic strategies against aneuploid tumors.
